| Primary |
| Cystic Fibrosis |
18.8% |
| Tuberculosis |
15.6% |
| Pyrexia |
12.5% |
| Lung Infection |
9.4% |
| Bronchiectasis |
6.3% |
| Infection Prophylaxis |
6.3% |
| Lung Disorder |
6.3% |
| Pulmonary Tuberculosis |
6.3% |
| Acute Leukaemia |
3.1% |
| Back Pain |
3.1% |
| Chest Pain |
3.1% |
| Diarrhoea |
3.1% |
| Gout |
3.1% |
| Mycobacterium Abscessus Infection |
3.1% |
|
| Deafness |
10.0% |
| Wound Dehiscence |
10.0% |
| Dermatitis Bullous |
5.0% |
| Haemorrhage |
5.0% |
| Hearing Impaired |
5.0% |
| Hypoxic Encephalopathy |
5.0% |
| Infusion Site Infection |
5.0% |
| Medication Error |
5.0% |
| Mycobacterium Avium Complex Infection |
5.0% |
| Neutropenia |
5.0% |
| Photopsia |
5.0% |
| Rash |
5.0% |
| Supraventricular Tachycardia |
5.0% |
| Thrombocytopenia |
5.0% |
| Tinnitus |
5.0% |
| Tubulointerstitial Nephritis |
5.0% |
| Urticaria |
5.0% |
| Vasculitis |
5.0% |
|
| Secondary |
| Prophylaxis |
18.4% |
| Product Used For Unknown Indication |
17.7% |
| Hiv Infection |
6.3% |
| Sepsis |
5.6% |
| Enterococcal Infection |
5.2% |
| Escherichia Infection |
5.2% |
| Respiratory Tract Infection Bacterial |
5.2% |
| Drug Use For Unknown Indication |
4.5% |
| Bacterial Infection |
4.2% |
| Unevaluable Event |
3.8% |
| Bacterial Sepsis |
3.5% |
| Respiratory Tract Infection |
3.5% |
| Immunosuppressant Drug Therapy |
3.1% |
| Nausea |
2.8% |
| Escherichia Sepsis |
2.4% |
| Gout |
2.1% |
| Vomiting |
2.1% |
| Diuretic Therapy |
1.7% |
| Anti-infective Therapy |
1.4% |
| Eschar |
1.4% |
|
| Toxic Skin Eruption |
16.3% |
| Jaundice |
14.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
9.3% |
| Agranulocytosis |
7.0% |
| Pyrexia |
7.0% |
| Pulmonary Tuberculosis |
4.7% |
| Renal Failure Acute |
4.7% |
| Subdural Haematoma |
4.7% |
| Therapy Non-responder |
4.7% |
| Thrombocytopenia |
4.7% |
| Acute Generalised Exanthematous Pustulosis |
2.3% |
| Cholestasis |
2.3% |
| Condition Aggravated |
2.3% |
| Delusion |
2.3% |
| Grand Mal Convulsion |
2.3% |
| Haematoma |
2.3% |
| Heparin-induced Thrombocytopenia |
2.3% |
| Lactic Acidosis |
2.3% |
| Neutropenia |
2.3% |
| Photopsia |
2.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
21.8% |
| Product Used For Unknown Indication |
13.1% |
| Prophylaxis |
11.0% |
| Acute Myeloid Leukaemia |
7.1% |
| Antibiotic Prophylaxis |
5.2% |
| Diffuse Large B-cell Lymphoma |
5.2% |
| Infection Prophylaxis |
3.3% |
| Meningitis |
3.1% |
| Patent Ductus Arteriosus |
3.1% |
| Sepsis |
3.1% |
| Bronchitis |
2.9% |
| Infection |
2.9% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Sedation |
2.7% |
| Pneumonia |
2.3% |
| Bronchopulmonary Dysplasia |
2.1% |
| Dyspepsia |
2.1% |
| Necrotising Colitis |
2.1% |
| Pain |
2.1% |
| Pulmonary Oedema |
2.1% |
|
| Septic Shock |
11.4% |
| Pyrexia |
8.9% |
| Sepsis |
7.6% |
| Agranulocytosis |
6.3% |
| Retinopathy Of Prematurity |
6.3% |
| Thrombocytopenia |
6.3% |
| Venoocclusive Liver Disease |
6.3% |
| Tachycardia |
5.1% |
| Tremor |
5.1% |
| Ventricular Extrasystoles |
5.1% |
| Bone Marrow Failure |
3.8% |
| Renal Failure |
3.8% |
| Skin Test Positive |
3.8% |
| Urinary Tract Infection |
3.8% |
| Weight Increased |
3.8% |
| Death |
2.5% |
| Febrile Neutropenia |
2.5% |
| Hepatocellular Injury |
2.5% |
| Pneumonia |
2.5% |
| Pneumothorax |
2.5% |
|
| Interacting |
|
|
